Anti-CXCL12 (NOX-A12) combined with pembrolizumab can prolong the time on trial treatment compared with their last standard treatment and activate the Th1 immune response in patients with metastatic colorectal and pancreatic cancer [30]. The gene discussed is CXCL12; the disease is familial pancreatic carcinoma.